Business Wire

OWL-LABS

Share
Owl Labs Teams with Ingram Micro to Widen Distribution of the Meeting Owl Pro within Europe

Owl Labs , the award-winning leader in immersive and collaborative video conferencing technology and services, today announced an alliance with Ingram Micro, the world’s largest distributor and provider of technology services and solutions. The new distribution agreement expands Owl Labs’ reach across Europe and strengthens Owl Labs’ presence within key European markets.

Through Owl Labs working relationship with Ingram Micro, Owl Labs will now be able to expand the reach and accessibility of its award-winning flagship product, the Meeting Owl Pro, to one centralised distribution warehouse in Straubing, Germany, and from that single point will support its supply chain into 17 distribution centers across Europe, trading across all 28 countries. Ingram Micro serves a diverse base of resellers and 2,000+ of the world’s most recognized IT and mobility technology brands.

With the rapid adoption of hybrid work and remote teams, maintaining effective communication and collaboration regardless of location is more crucial than ever. As more diverse and flexible working patterns continue to become increasingly popular, companies will need to find a better way to connect employees, whether they are in-office or at home. Companies can achieve a seamless collaborative team experience no matter where employees are located with the Meeting Owl Pro. Powered by Owl Labs’ proprietary intelligence technology, the Meeting Owl Pro automatically focuses on who is speaking in a room using audio and visual cues from its high-definition 360° camera, as well as eight microphones and tri-speakers, that have a pickup range of five meters. Through this technology the smart device is able to create a fully immersive, near face-to-face experience for all participants involved, and is also compatible with all popular video conferencing platforms.

“We are thrilled to team up with Ingram Micro, increasing our reach and presence across Europe to expand and strengthen our business. This alliance will make it easier for businesses and educational institutions based in Europe to use Owl Labs’ collaboration technology to help maintain and facilitate clear and effective communication with employees or students, no matter their location.” states Frank Weishaupt, CEO of Owl Labs. “As hybrid and flexible working rises in popularity, there is an increased demand in products and services that help productivity and allow hybrid teams to communicate effectively. We look forward to meeting this demand through our partnership with Ingram Micro.”

Owl Labs' products are used by 50,000+ companies in 156 countries across a wide array of categories, including the likes of the Ogilvy, ClearScore, Bern University of Applied Science, and Prague College. Owl Labs has been recently named AV Technology Awards Communication Technology of the Year, as well as German Design Award Winners and Red Dot Award Recipient. The Owl Labs' Meeting Owl Pro is also named in TIME's List Of The 100 Best Inventions Of 2020.

Having the ability to work from anywhere and communicate clearly and securely from everywhere is critical to the future of work,” states Joost Boon, director, Advanced Solutions, UCC Supply Chain and Business Operations, Pan Europe GmbH, Ingram Micro. “We are pleased to welcome Owl Labs to the Ingram Micro Pan Europe portfolio, and look forward to working together with our channel partners to generate greater awareness and demand for Owl Lab’s innovative and immersive video conferencing technology solutions.”

About Owl Labs
Owl Labs is a collaborative technology company revolutionizing the way we connect. Owl Labs creates deeply immersive and inclusive meeting experiences for today’s hybrid workforce and virtual classroom. The company’s flagship product, the award-winning Meeting Owl, features a wifi-enabled, 360-degree camera, mic, and speaker powered by proprietary technology with an automatic zoom that responds to who’s speaking. In 2020, the Meeting Owl Pro was named in TIME’s 100 Best Innovations .

Owl Labs continues to champion the hybrid work movement with its annual State of Remote Work Report . To learn more about Owl Labs and the full product suite and to join the Work From Anywhere Movement, please visit www.owllabs.com .

About Ingram Micro
Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables its business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and dependability that come from decades of proven relationships, set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye